[Effectiveness and tolerance of cefixime in bacterial urinary tract infections in patients with myelomeningocele].
28 myelomeningocele patients (aged 2-30 years) with clinical symptoms of acute UTI participated in this open uncontrolled clinical trial at the Orthopedic University Hospital of Heidelberg (Dir.: Prof. Dr. H. Cotta). 4 patients were treated with 200 mg cefixime tablets bid, 24 patients received 4 mg/kg body weight cefixime suspension bid, according to age and weight of the patients. The duration of treatment was 6-10 days. Clinical and microbiological examinations were carried out before therapy as well as 1 day and 5 to 9 days after the end of treatment. The data of 25 patients could be evaluated for bacteriological and clinical efficacy. 5-9 days after treatment in 22 patients (88%) complete recovery was stated. In 3 patients a reinfection occurred. In 24 patients (96%) the baseline pathogens were eliminated under cefixime therapy. 5-9 days after the end of treatment in 3 patients reinfection was observed. Clinical side effects could be detected in 1 patient (vomiting). These results indicate that the oral cephalosporin cefixime is efficient and well tolerated in complicated UTI of myelomeningocele patients.
Carstens
C
C
Orthopädische Universitätsklinik Heidelberg.
Hostalek
U
U
D000293:Adolescent; D000328:Adult; D000892:Anti-Infective Agents, Urinary / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001437:Bacteriuria / Q000097:blood / Q000188:drug therapy / Q000382:microbiology; D020682:Cefixime; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008591:Meningomyelocele / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D012008:Recurrence; D001750:Urinary Bladder, Neurogenic / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
D000892:Anti-Infective Agents, Urinary; D020682:Cefixime; D002439:Cefotaxime
Wirksamkeit und Verträglichkeit von Cefixim bei bakteriellen Infektionen der Harnwege bei Patienten mit Myelomeningozele.